Core Viewpoint - Broadmark Realty Capital Inc. is facing a class action lawsuit related to its merger with Ready Capital Corporation, alleging misleading statements in the proxy statement used for shareholder approval [3][4]. Company Overview - Broadmark Realty Capital Inc. and Ready Capital Corporation are classified as real estate investment trusts (REITs) [3]. Merger Details - The merger between Broadmark and Ready Capital was approved by Broadmark shareholders on May 30, 2023, and finalized on May 31, 2023 [3]. Allegations in the Lawsuit - The lawsuit claims that the proxy statement contained materially false and/or misleading statements and omitted key facts [3]. - Specific allegations include: 1. A significant portion of borrowers in Ready Capital's loan portfolio were experiencing financial distress due to rising interest rates, increasing their borrowing costs [5]. 2. An oversupply of multifamily properties in Ready Capital's core markets limited borrowers' ability to raise rents to offset growing debt obligations [5]. 3. A major development project, a Ritz-Carlton in Portland, Oregon, faced severe setbacks, including cost overruns, construction delays, and funding shortfalls, representing approximately $500 million of Ready Capital's acquired loan portfolio [5]. 4. Ready Capital's Current Expected Credit Loss (CECL) reserves and projected credit losses were significantly understated due to these issues [5]. 5. Financial projections from Ready Capital, including estimates of Distributable Earnings per share, dividends per share, and book value per share, lacked a reasonable basis when issued [5]. Legal Representation - The plaintiffs are represented by Robbins Geller Rudman & Dowd LLP, a firm experienced in prosecuting investor class actions involving financial fraud [4].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation strategy and dividend policies during the specified Class Period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased Organon securities between November 3, 2022, and April 30, 2025 [1]. - Investors have until July 22, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against Organon - The lawsuit claims that Organon concealed critical information about its capital allocation strategy, particularly regarding its quarterly dividend payout [3]. - Despite public statements indicating that maintaining the dividend was a top priority, Organon had adopted a debt reduction strategy that conflicted with this commitment [3]. - Following the acquisition of Dermavant Sciences Ltd., Organon intended to prioritize debt reduction, which led to a significant cut in its dividend [3]. Group 3: Financial Impact - On May 1, 2025, Organon announced a drastic reduction in its quarterly dividend from $0.28 to $0.02 per share [4]. - This announcement resulted in a stock decline of more than 27% [4].

Core Viewpoint - Red Cat Holdings, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its production capacity and the value of its contracts, leading to significant stock price declines during the class period from March 18, 2022, to January 15, 2025 [1][3]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Red Cat overstated the production capacity of its Salt Lake City facility and the potential of its Short Range Reconnaissance Program of Record Tranche 2 contract [3]. - On July 27, 2023, Red Cat revealed that its Salt Lake City facility could only produce 100 drones per month, which was a significant reduction from previously stated expectations [4]. - Following this disclosure, Red Cat's stock price fell nearly 9% [4]. Group 2: Financial Performance and Impact - On September 23, 2024, Red Cat reported a first-quarter fiscal year 2025 loss of $0.17 per share, missing expectations, and revenue of $2.8 million, which was $1.07 million below forecasts [5]. - The company admitted that retooling its Salt Lake City facility for high-volume production and pausing manufacturing of the Teal 2 directly impacted sales, resulting in a stock decline of over 25% [5]. Group 3: Further Developments and Stock Decline - On January 16, 2025, Kerrisdale Capital published a report questioning the validity of the SRR contract, stating it was smaller and less favorable than previously communicated [6]. - This report raised concerns about the feasibility of constructing a mass-production facility within two years with an investment of less than $1 million, leading to a stock decline of more than 21% over the following two trading sessions [6].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) investors of a class action representing investors that bought securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"). Iovance investors have until July 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F ...

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation, alleging that the company misrepresented the effectiveness of its restructuring plan following a failed merger with Amazon, leading to significant investor losses [3][4]. Group 1: Lawsuit Details - The class action represents investors who purchased iRobot securities between January 29, 2024, and March 11, 2025, with a deadline of September 5, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that iRobot overstated the stability provided by its restructuring plan, raising doubts about its long-term viability as an independent company [3]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share for Q4 and the full year 2024, with revenue of $172 million, marking a 44% decline from the previous year [4]. - The company's statement indicated "substantial doubt" about its ability to continue as a going concern for at least the next 12 months, which led to a stock price drop of over 51% following the announcement [4].

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit from investors who purchased securities during the specified Class Period, alleging misleading statements regarding Medicaid cost trends and financial guidance [1][3]. Group 1: Class Action Details - The class action represents investors who bought Elevance securities between April 18, 2024, and October 16, 2024, with a deadline of July 11, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance's management misled investors about the Medicaid redetermination process, claiming they were monitoring cost trends and that premium rates were adequate [3]. - It is claimed that the redetermination process resulted in a higher-risk Medicaid population, which was not accurately reflected in Elevance's financial projections or rate negotiations for 2024 [3].

Core Viewpoint - Avis Budget Group, Inc. is facing a class action lawsuit due to alleged misleading statements and undisclosed information regarding its fleet rotation strategy, which has led to significant financial losses and impairment charges [2][3]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Avis securities between February 16, 2024, and February 10, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Avis Budget - The lawsuit claims that Avis Budget executed a plan to aggressively accelerate fleet rotation, which shortened the useful life of vehicles in the Americas segment, reducing their recoverable value [2]. - As a result of this strategy, Avis Budget is expected to recognize billions of dollars in impairment charges and face substantial losses [2]. - The financial performance of Avis Budget was significantly negatively impacted, leading to an overstated financial condition and business outlook [2]. Group 3: Financial Results and Leadership Changes - On February 11, 2025, Avis Budget reported a quarterly loss of $1.96 billion, or $55.66 per share, compared to a profit of $259 million, or $7.10 per share, for the same period the previous year [3]. - The loss was attributed to a change in strategy regarding fleet rotations, resulting in a one-time non-cash impairment of $2.3 billion and additional non-cash charges of $180 million [3]. - Following the announcement of these results, Avis Budget's stock price dropped nearly 7% [3]. - The CEO, Joseph A. Ferraro, is set to step down, transitioning to a Board Advisor role, with Brian Choi taking over as CEO on July 1, 2025 [3].

Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors regarding the company's revenue and growth challenges, particularly related to a failed FDA inspection at its Indore facility [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Viatris securities between August 8, 2024, and February 26, 2025, with a deadline of June 3, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and complimentary case evaluations [2]. Group 2: Allegations Against Viatris - The lawsuit claims that Viatris downplayed the seriousness of the failed FDA inspection and its consequences, leading to a false impression of the company's stability [3]. - It is alleged that Viatris underestimated the impact of the FDA inspection failure, which resulted in significant setbacks, including ongoing remediation efforts and disruptions in manufacturing and shipping key products like Lenalidomide [4]. Group 3: Financial Impact - On February 27, 2025, Viatris reported disappointing fourth-quarter and full-year 2024 financial results, along with guidance for fiscal year 2025 that reflected the expected financial effects of the FDA warning letter [5]. - Following this announcement, Viatris' stock price experienced a decline of over 15% [5].

Core Viewpoint - UnitedHealth Group is facing legal scrutiny due to allegations of improper denial of health coverage to enhance profitability, which has led to regulatory attention and public criticism [3]. Group 1: Company Overview - UnitedHealth Group operates as a health insurance and health care services provider [3]. - The company has been accused of pursuing a corporate strategy that improperly denies health coverage [3]. Group 2: Legal and Regulatory Issues - Investors have until July 7, 2025, to file a lead plaintiff motion related to the allegations against UnitedHealth [1]. - The Portnoy Law Firm is offering complimentary case evaluations for investors seeking to recover losses [2]. - Following public outcry, UnitedHealth has reportedly reduced its practice of denying health insurance claims, yet continues to affirm its previous financial guidance [4]. Group 3: Financial Impact - The allegations and subsequent public scrutiny have significant implications for UnitedHealth's reputation and financial performance, particularly in light of the CEO's death in December 2024 [3].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises SoundHound AI, Inc. ("SoundHound" or the "Company") (NASDAQ: SOUN) investors of a class action representing investors that bought securities between May 10, 2024 and March 3, 2025, inclusive (the "Class Period"). SoundHound AI, Inc. investors have until May 27, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney ...